Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA Multicenter Phase II Trial

Leukemia

Volumn 28, Issue 3, 2014, Pages 642-648

  Cortelezzi, A ^a   Sciume M ^a   Liberati, A M ^b   Vincenti, D ^a   Cuneo, A ^c   Reda, G ^a   Laurenti, L ^d   Zaja, F ^e   Marasca, R ^f   Chiarenza, A ^g   Gritti, G ^h   Orsucci, L ⁱ   Storti, S ^j   Angelucci, E ^k   Cascavilla, N ^l   Gobbi, M ^m   Mauro, F R ⁿ   Morabito, F ^o   Fabris, S ^a   Piciocchi, A ^p   Vignetti, M ⁿ   Neri, A ^a   Rossi, D ^q   Giannarelli, D ^r   Guarini, A ⁿ   Foa R ⁿ   more..

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h OSPEDALI RIUNITI   (Italy)

ⁱ MOLINETTE HOSPITAL   (Italy)

^j CATHOLIC UNIVERSITY   (Italy)

^k Ospedale Oncologico A Businco   (Italy)

^l CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o Unit of Geriatrics   (Italy)

^p GIMEMA Data Center   (Italy)

^q UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^r REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Bendamustine; Chronic lymphocytic leukemia; Ofatumumab; Relapse

Indexed keywords

BENDAMUSTINE; OFATUMUMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; HYPOTENSION; INFECTION; LIVER TOXICITY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYREXIA IDIOPATHICA; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; NITROGEN MUSTARD COMPOUNDS; RECURRENCE;

EID: 84895833178     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.334     Document Type: Article

References (29)

1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
2. Dhner H, Stilgenbauer S, Benner A, Leupolt E, Krö ber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
3. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
4. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458-1461.
5. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
6. Puente XS, Pinyol M, Quesada V, Conde L, Ordón ez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
7. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
8. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521-529.
9. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-Type chronic lymphocytic leukemia. Blood 2012; 119: 2854-2862.
10. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
11. Flinn I, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793-798.
12. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
13. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007; 370: 230-239.
14. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078.
15. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016-3024.
16. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
17. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
18. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-Term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
19. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762.
20. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-4384.
21. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-3566.
22. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al. Ofatumumab as single-Agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-1755.
23. Wierda WG, Padmanabhan S, Chan GW, Stilgenbauer S, Williams CD, Hellmann A et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the phase 2 international study. Blood 2011; 118: 5126-5129.
24. Rawstron AC, Villamor N, Ritgen M, Bö ttcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956-964.
25. Bottcher S, Stilgenbauer S, Busch R, Bru?ggemann M, Raff T, Pott C et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab containing immunochemotherapy: A comparative analysis. Leukemia 2009; 23: 2007-2017.
26. National Cancer Institute. Common Terminology Criteria for Adverse Events v. 4.0 (CTCAE) http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
28. Ferrajoli A, Falchi L, O'Brien S, Wierda W, Faderl S, Smith SC et al. Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Results of a Phase II Trial. Blood (ASH Annual Meeting Abstracts) 2012; 120: 720.
29. Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988..